New anti obesity drug for 2007

Wynyard, Ruth
June 2006
New Zealand Doctor;6/14/2006, p6
Reports that the anti-obesity drug rimonabant will be available in the Australian market by the end of 2007. Possible availability of the drug in the U.S. in 2008; View of nutritionist and professor Jim Mann on the drug.


Related Articles

  • Options for treating obesity. Campbell, Ian // GP: General Practitioner;4/26/2002, p70 

    Focuses on the options for general practitioners in treating obesity. Effectiveness of anti-obesity drugs; Requirements for drug administration; Importance of setting realistic targets.

  • Long-Term Results of Drug Treatment for Obesity. SLAWSON, DAVID // American Family Physician;3/1/2014, Vol. 89 Issue 5, p389 

    The article presents answers to a question on whether weight loss medications are effective as long-term treatment for obesity.

  • New experimental drug helps obese patients lose weight.  // New York Amsterdam News;02/25/99, Vol. 90 Issue 9, p14 

    Highlights the results of a study conducted at Baylor College of Medicine in Houston, Texas indicating the potency of orlistat to promote weight loss among obese patients. Need for the combination of moderate-calorie diet; Mechanism of the drug's action; Adverse reactions.

  • 5 that work. Nachatelo, Melissa // Natural Health;May/Jun2001, Vol. 31 Issue 4, p70 

    Presents information about different natural diet supplements used in the management of obesity. Green tea; Ephedra; Chromium.

  • Focus On Orlistat: A Nonsystemic Inhibitor Of Gastrointestinal Lipase For Weight Reduction In The Management Of Obesity. Chow, Moses S.S.; Reddy, Prabashni // Formulary;Oct98, Vol. 33 Issue 10, p943 

    Discusses orlistat, a nonsystemic inhibitor of gastrointestinal lipase for weight reduction in the management of obesity. Chemistry and pharmacology; Pharmacokinetics; Clinical trials; Guidelines for obesity therapy; Adverse effects; Drug interaction; Dosage. INSET: Formulary Considerations.

  • Profit in Loss. Wellner, Alison Stein // American Demographics;Jul2000, Vol. 22 Issue 7, p46 

    Discusses the development of the XeniCare program offered to patients using the Roche Laboratories' Xenical prescription obesity drug.

  • GPs should join debate on potential risk versus reward of obesity drug. Castaneda, Reynald // New Zealand Doctor;10/8/2014, p14 

    The article focuses on the debate by general practitioners (GP) and clinicians in New Zealand on the risks and reward of the obesity drug phentermine.

  • A pharmacologic approach to obesity. Lucas, Charles P.; Segal, Karen R.; Hauptman, Jonathan // Contemporary OB/GYN;Jun2000, Vol. 45 Issue 6, p18 

    Evaluates the effectiveness of orlistat for the treatment of obesity. Gender-specific effects of obesity; Effect of orlistat on weight loss; Side effects of orlistat. INSET: Fighting obesity.

  • Obesity market to balloon by 2012, new products set to dominate.  // PharmacoEconomics & Outcomes News;7/17/2004, Issue 457, p11 

    Reports on the possible growth of the market for drugs used in treating obesity according to results of an analysis conducted by Datamonitor. Types of drugs for treating obesity to be introduced in the market.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics